Lutetium-177 PSMA Therapy: Scientific Evidence Supporting the Slowing of Disease Progression in Prostate Cancer
Prostate cancer, due to its progressive nature, can spread over time to the bones, lymph nodes, or other organs. In recent years, Lutetium-177 PSMA therapy has emerged as a modern treatment option with the potential to slow down this progression.
The therapy specifically targets cancer cells that express a structure called PSMA (Prostate-Specific Membrane Antigen) and delivers radiation directly to the tumor tissue.
Thanks to this targeted approach, treatment effectiveness is enhanced while healthy tissues are better preserved.
The Effect of the Treatment on Disease Progression
Lutetium-177 PSMA therapy helps control prostate cancer by reducing the biological progression rate of the disease.
The following clinical effects may be observed after treatment:
- Slowing of tumor growth rate
- Tendency for existing metastases to shrink
- Reduction in the rate of new metastasis formation
- Significant relief from pain and related symptoms
These effects contribute meaningfully to both the patient’s survival and overall quality of life.
How Do Scientific Studies Support This Effect?
Lutetium-177 PSMA therapy is a treatment method whose effectiveness has been proven through international clinical trials:
VISION Study
It was demonstrated that in advanced-stage prostate cancer, the treatment slows disease progression and extends overall survival.
TheraP Study
The study showed that Lutetium-177 PSMA therapy is better tolerated than chemotherapy and provides stronger tumor responses.
PSMAddition Study
According to recent findings, this therapy significantly reduces the risk of disease progression not only in advanced stages but also in earlier, hormone-sensitive stages of prostate cancer.
These three major studies are among the most important references that strengthen the scientific foundation of this treatment.
Contribution in Terms of Prognosis
"Prognosis" is a medical term used to describe how a disease is expected to progress over time.
Lutetium-177 PSMA therapy may:
- Prolong the time to disease progression
- Provide a sustained period of stable disease
- Reduce pain and bone-related symptoms
- Help maintain daily life activities
These features demonstrate that the treatment offers broad benefits that go beyond simply shrinking the tumor.
What Is the Treatment Process Like?
The application of the treatment is generally very comfortable:
- It is administered as a single-session intravenous injection.
- The procedure is typically painless.
- Most patients can be discharged the same day.
- Side effects are usually mild, such as temporary fatigue or dry mouth.
For these reasons, the treatment is considered a well-tolerated and convenient option for many patients.
Conclusion
Lutetium-177 PSMA therapy is a modern, targeted treatment that has been scientifically proven to slow the progression of prostate cancer.
Findings from the VISION, TheraP, and PSMAddition studies demonstrate that this therapy can make a significant contribution to both survival time and quality of life in patients.
